跳至主要内容
临床试验/DRKS00017037
DRKS00017037招募中未知

A randomised, double-blind, placebo-controlled study on the impact of doxycycline on aversive memory in healthy individuals - DoxAv

Department of Psychiatry, Psychotherapy, Psychosomatics, University of Zurich0 个研究点目标入组 560 人开始时间: 2019年11月5日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
560

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 40 Years(—)
性别
All

入选标准

  • Informed Consent as documented by signature
  • - Age 18 – 40 years

排除标准

  • Allergy to doxycycline or to any other ingredient in the named drugs
  • Use of any drugs in the 2 weeks prior to the study with the exception of contraceptive drugs and incidental use of NSARs or paracetamol
  • Women who are pregnant or breast feeding,
  • Intention to become pregnant during the course of the study,
  • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
  • Any history of psychiatric, neurological, addiction, or systemic/rheumatic disease
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the study, e.g. due to language problems
  • Participation in another study with investigational drug within 30 days preceding and during the present study,
  • Previous enrolment into the current study,
  • Members of the study team and their family members and dependants
  • Regular work in a medical profession
  • Life time history of being a victim of interpersonal violence or other potentially traumatic experience, or close relative of a person with such history

研究者

发起方
Department of Psychiatry, Psychotherapy, Psychosomatics, University of Zurich

相似试验

已完成
不适用
A randomised, double-blind, placebo-controlled study evaluating Palmitoylethanolamide for diabetic-related peripheral neuropathic pain, inflammation and quality of lifediabetic-related peripheral neuropathyMetabolic and Endocrine - DiabetesNeurological - Other neurological disorders
ACTRN12620001302943Gencor Pacific Ltd70
进行中(未招募)
1 期
Study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscular Dystrophy
EUCTR2017-001629-41-NLITALFARMACO S.P.A.48
进行中(未招募)
不适用
A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect short-term statin effects in patients with increased cardiovascular risk
EUCTR2008-002332-15-SEAstraZeneca AB
进行中(未招募)
1 期
Clinical trial to study the safety and tolerability of EP395 in comparison with placebo in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855
EUCTR2021-005787-22-DEEpiEndo Pharmaceuticals60
进行中(未招募)
1 期
A study to test a potential new treatment for COPD patients suffering from the common cold or influenza.Patients with Chronic Obstructive Pulmonary Disease (COPD). In part 1 of the study the patients are in stable state. In part 2 of the study patients have a respiratory virus infection (i.e. cold or flu virus).MedDRA version: 21.1 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855
EUCTR2017-003679-75-GBSynairgen Research Limited130
A randomised, double-blind, placebo-controlled study... | 临床试验